← Leaderboards
Peter Edwin Wright
Scripps Research Institute, The
$37,349,507
Attributed
$38,851,539
Total exposure
81
Grants
59
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,851,539 · 81
By mechanism
R01$29,888,414 · 7
M01$4,920,575 · 66
R35$1,372,500 · 1
P01$1,200,927 · 3
S10$900,386 · 2
R37$558,737 · 1
Top collaborators
- Ashok A Deniz5 shared
Most similar at Scripps Research Institute, The
Same institution · by research overlap
- Sandra E Encalada$6,652,685
- Natalia Reixach$2,056,474
- Michael Petrascheck$13,347,538
- Irit Rappley$105,268
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightStructureMolecularPlayProteinsGrantResearch PersonnelComplexUnited States National Institutes Of HealthFundingSourceComputer Retrieval Of Information On Scientific Projects DatabaseResourcesInstitutionBinding (Molecular Function)SiteKineticsBasePathway InteractionsMediatingSafetyResponseTumor Suppressor ProteinsEvent
Grant awards (159)
Molecular mechanisms of transthyretin amyloidosis$566,635
R01 · FY2025 · DK · contact PI
Structural characterization of large eukaryotic proteins containing both folded and disordered domains$460,000
R35 · FY2025 · GM · contact PI
Structural characterization of large eukaryotic proteins containing both folded and disordered domains$460,000
R35 · FY2024 · GM · contact PI
Molecular mechanisms of transthyretin amyloidosis$465,449
R01 · FY2023 · DK · contact PI
Structural characterization of large eukaryotic proteins containing both folded and disordered domains$452,500
R35 · FY2023 · GM · contact PI
Molecular Basis for Regulation of Cellular Stress Response Pathways by CBP/p300$472,569
R01 · FY2022 · CA · contact PI
Molecular mechanisms of transthyretin amyloidosis$456,448
R01 · FY2022 · DK · contact PI
Molecular basis for regulation of CREB by cell stress and retroviral oncoproteins$599,187
R01 · FY2021 · CA · contact PI
Molecular Basis for Regulation of Cellular Stress Response Pathways by CBP/p300$482,214
R01 · FY2021 · CA · contact PI
Molecular mechanisms of transthyretin amyloidosis$456,448
R01 · FY2021 · DK · contact PI
Dynamic modulation of p53 activity by its disordered regulatory domains$414,512
R01 · FY2021 · GM · contact PI
Molecular basis for regulation of CREB by cell stress and retroviral oncoproteins$599,187
R01 · FY2020 · CA · contact PI
Molecular Basis for Regulation of Cellular Stress Response Pathways by CBP/p300$482,214
R01 · FY2020 · CA · contact PI
Molecular mechanisms of transthyretin amyloidosis$456,448
R01 · FY2020 · DK · contact PI
Dynamic modulation of p53 activity by its disordered regulatory domains$414,512
R01 · FY2020 · GM · contact PI
Molecular basis for regulation of CREB by cell stress and retroviral oncoproteins$581,211
R01 · FY2019 · CA · contact PI
Molecular Basis for Regulation of Cellular Stress Response Pathways by CBP/p300$467,747
R01 · FY2019 · CA · contact PI
Dynamic modulation of p53 activity by its disordered regulatory domains$414,512
R01 · FY2019 · GM · contact PI
Molecular basis for regulation of CREB by cell stress and retroviral oncoproteins$599,187
R01 · FY2018 · CA · contact PI
Molecular Basis for Regulation of Cellular Stress Response Pathways by CBP/p300$506,244
R01 · FY2018 · CA · contact PI
Dynamic modulation of p53 activity by its disordered regulatory domains$414,512
R01 · FY2018 · GM · contact PI
Molecular basis for regulation of CREB by cell stress and retroviral oncoproteins$625,292
R01 · FY2017 · CA · contact PI
Characterization of the unfolding landscape of human transthyretin$418,688
R01 · FY2017 · DK · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$400,360
R01 · FY2017 · GM · contact PI
Characterization of the unfolding landscape of human transthyretin$418,688
R01 · FY2016 · DK · contact PI
Structural basis for CBP/p300 transcriptional regulation$407,364
R01 · FY2016 · CA · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$400,360
R01 · FY2016 · GM · contact PI
Characterization of the unfolding landscape of human transthyretin$412,163
R01 · FY2015 · DK · contact PI
Structural basis for CBP/p300 transcriptional regulation$407,364
R01 · FY2015 · CA · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$394,120
R01 · FY2015 · GM · contact PI
Characterization of the unfolding landscape of human transthyretin$412,163
R01 · FY2014 · DK · contact PI
Structural basis for CBP/p300 transcriptional regulation$395,143
R01 · FY2014 · CA · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$394,120
R01 · FY2014 · GM · contact PI
Characterization of the unfolding landscape of human transthyretin$412,163
R01 · FY2013 · DK · contact PI
Structural basis for CBP/p300 transcriptional regulation$382,922
R01 · FY2013 · CA · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$369,805
R01 · FY2013 · GM · contact PI
Structural basis for CBP/p300 transcriptional regulation$407,364
R01 · FY2012 · CA · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$383,218
R01 · FY2012 · GM · contact PI
Structural basis for CBP/p300 transcriptional regulation$407,364
R01 · FY2011 · CA · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$383,218
R01 · FY2011 · GM · contact PI
Recognition of Regulatory and Pathogenic RNA by Muscleblind Zinc Fingers$469,013
R01 · FY2010 · GM · contact PI
High Performance Digital NMR Spectrometer Console$424,267
S10 · FY2010 · RR · contact PI
Structural basis for CBP/p300 transcriptional regulation$419,962
R01 · FY2010 · CA · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$387,088
R01 · FY2010 · GM · contact PI
Recognition of Regulatory and Pathogenic RNA by Muscleblind Zinc Fingers$473,750
R01 · FY2009 · GM · contact PI
Structural basis for CBP/p300 transcriptional regulation$419,962
R01 · FY2009 · CA · contact PI
Structural Characterization of Globin Folding Pathways$343,654
R01 · FY2009 · DK · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$322,929
R01 · FY2009 · GM · contact PI
Recognition of Regulatory and Pathogenic RNA by Muscleblind Zinc Fingers$77,735
R01 · FY2009 · GM · contact PI
Structural basis for CBP/p300 transcriptional regulation$55,502
R01 · FY2009 · CA · contact PI
Recognition of Regulatory and Pathogenic RNA by Muscleblind Zinc Fingers$473,750
R01 · FY2008 · GM · contact PI
Structural basis for CBP/p300 transcriptional regulation$419,962
R01 · FY2008 · CA · contact PI
Structural Characterization of Globin Folding Pathways$343,654
R01 · FY2008 · DK · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$322,929
R01 · FY2008 · GM · contact PI
HVTN 204$30,728
M01 · FY2008 · RR · contact PI
HVTN 060: PHASE I TRIAL$21,573
M01 · FY2008 · RR · contact PI
HVTN 068: PHASE I TRIAL$17,275
M01 · FY2008 · RR · contact PI
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CLADE B$15,444
M01 · FY2008 · RR · contact PI
International Conference on Magnetic Resonance in Biological Systems 2008$10,000
R13 · FY2008 · GM · contact PI
SHINGLES PREVENTION STUDY CONTINUED$8,047
M01 · FY2008 · RR · contact PI
LANGAT/DENGUE VACCINE FOR TICK BORNE ENCEPHALITIS$6,138
M01 · FY2008 · RR · contact PI
HVTN 054: PHASE I TRIAL$2,627
M01 · FY2008 · RR · contact PI
WEST NILE/DENGUE VACCINE VIRUS$2,436
M01 · FY2008 · RR · contact PI
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CTL$2,229
M01 · FY2008 · RR · contact PI
HVTN 065: PHASE I TRIAL$2,149
M01 · FY2008 · RR · contact PI
EVALUATION OF HIV INFECTION OR VACCINE INDUCED POSITIVITY IN HIV VACCINE$1,672
M01 · FY2008 · RR · contact PI
HVTN 057: PHASE I TRIAL$1,592
M01 · FY2008 · RR · contact PI
HVTN 042 AVENTIS PATEUR- LIPO-5 AND ALVAC-HIV VACCINES IN HEALTHY, HIV-1 UNIN$1,274
M01 · FY2008 · RR · contact PI
HVTN 059: PHASE I TRIAL$955
M01 · FY2008 · RR · contact PI
A WORLD WIDE, PHASE I, DOSE ESCALATING STUDY OF THE SAFETY, TOLERABILITY, AND$557
M01 · FY2008 · RR · contact PI
A PROBE STUDY OF THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF A THREE-DOSE$239
M01 · FY2008 · RR · contact PI
A PROBE STUDY OF THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF HUMAN IMMUNO$159
M01 · FY2008 · RR · contact PI
Recognition of Regulatory and Pathogenic RNA by Muscleblind Zinc Fingers$466,000
R01 · FY2007 · GM · contact PI
Structural basis for CBP/p300 transcriptional regulation$413,092
R01 · FY2007 · CA · contact PI
NMR STRUCTURAL STUDIES OF PRION PROTEINS WITH POINT MUTATIONS$389,121
P01 · FY2007 · AG · contact PI
HVTN 204$380,138
M01 · FY2007 · RR · contact PI
Structural Characterization of Globin Folding Pathways$344,006
R01 · FY2007 · DK · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$316,794
R01 · FY2007 · GM · contact PI
HVTN 060: PHASE I TRIAL$266,887
M01 · FY2007 · RR · contact PI
HVTN 068: PHASE I TRIAL$213,706
M01 · FY2007 · RR · contact PI
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CLADE B$191,057
M01 · FY2007 · RR · contact PI
SHINGLES PREVENTION STUDY CONTINUED$170,816
M01 · FY2007 · RR · contact PI
LANGAT/DENGUE VACCINE FOR TICK BORNE ENCEPHALITIS$130,287
M01 · FY2007 · RR · contact PI
WEST NILE/DENGUE VACCINE VIRUS$51,717
M01 · FY2007 · RR · contact PI
HVTN 054: PHASE I TRIAL$32,501
M01 · FY2007 · RR · contact PI
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CTL$27,573
M01 · FY2007 · RR · contact PI
HVTN 065: PHASE I TRIAL$26,591
M01 · FY2007 · RR · contact PI
EVALUATION OF HIV INFECTION OR VACCINE INDUCED POSITIVITY IN HIV VACCINE$20,681
M01 · FY2007 · RR · contact PI
HVTN 057: PHASE I TRIAL$19,698
M01 · FY2007 · RR · contact PI
HVTN 042 AVENTIS PATEUR- LIPO-5 AND ALVAC-HIV VACCINES IN HEALTHY, HIV-1 UNIN$15,756
M01 · FY2007 · RR · contact PI
HVTN 059: PHASE I TRIAL$11,818
M01 · FY2007 · RR · contact PI
A WORLD WIDE, PHASE I, DOSE ESCALATING STUDY OF THE SAFETY, TOLERABILITY, AND$6,893
M01 · FY2007 · RR · contact PI
A PROBE STUDY OF THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF A THREE-DOSE$2,954
M01 · FY2007 · RR · contact PI
A PROBE STUDY OF THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF HUMAN IMMUNO$1,970
M01 · FY2007 · RR · contact PI
Structure and Dynamics of Protein-Nucleic Acid Complexes$458,223
R01 · FY2006 · GM · contact PI
Structural basis for CBP/p300 transcriptional regulation$402,386
R01 · FY2006 · CA · contact PI
NMR STUDIES OF PRION PROTEINS WITH POINT MUTATIONS$373,455
P01 · FY2006 · AG · contact PI
Structural Characterization of Globin Folding Pathways$341,184
R01 · FY2006 · DK · contact PI
Protein Dynamics in Dihydrofolate Reductase Catalysis$326,255
R01 · FY2006 · GM · contact PI
HVTN 204$163,432
M01 · FY2006 · RR · contact PI
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CLADE B$161,207
M01 · FY2006 · RR · contact PI
HVTN 060: PHASE I TRIAL$143,420
M01 · FY2006 · RR · contact PI
HVTN 054: PHASE I TRIAL$143,420
M01 · FY2006 · RR · contact PI
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CTL$140,084
M01 · FY2006 · RR · contact PI
HVTN 059: PHASE I TRIAL$132,303
M01 · FY2006 · RR · contact PI
HVTN 057: PHASE I TRIAL$118,962
M01 · FY2006 · RR · contact PI
LANGAT/DENGUE VACCINE FOR TICK BORNE ENCEPHALITIS$85,992
M01 · FY2006 · RR · contact PI
CLINICAL TRIALS FOR THE EVALUATION OF CANDIDATE HIV-1 VACCINES IN NON-HIV-1$84,494
M01 · FY2006 · RR · contact PI
HVTN 042 AVENTIS PATEUR- LIPO-5 AND ALVAC-HIV VACCINES IN HEALTHY, HIV-1 UNIN$72,267
M01 · FY2006 · RR · contact PI
EVALUATION OF HIV INFECTION OR VACCINE INDUCED POSITIVITY IN HIV VACCINE$26,683
M01 · FY2006 · RR · contact PI
A WORLD WIDE, PHASE I, DOSE ESCALATING STUDY OF THE SAFETY, TOLERABILITY, AND$21,123
M01 · FY2006 · RR · contact PI
HVTN 052-VRC-HIVDNA 009-00-VP HIV VACCINE IN HEALTHY, HIV-1 UNINFECTED ADULTS$18,901
M01 · FY2006 · RR · contact PI
COMPARATIVE RANDOMIZED STUDY OF SAFETY AND IMMUNOGENICITY OF A NON-ADJUVANTED$419
M01 · FY2006 · RR · contact PI
Structure and Dynamics of Protein-Nucleic Acid Complexes$469,250
R01 · FY2005 · GM
Structural basis for CBP/p300 transcriptional regulation$412,070
R01 · FY2005 · CA
HVTN 042 AVENTIS PATEUR- LIPO-5 AND ALVAC-HIV VACCINES IN HEALTHY, HIV-1 UNIN$325,837
M01 · FY2005 · RR
HVTN 052-VRC-HIVDNA 009-00-VP HIV VACCINE IN HEALTHY, HIV-1 UNINFECTED ADULTS$324,048
M01 · FY2005 · RR
Structural Characterization of Globin Folding Pathways$320,861
R01 · FY2005 · DK
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CLADE B$279,541
M01 · FY2005 · RR
A WORLD WIDE, PHASE I, DOSE ESCALATING STUDY OF THE SAFETY, TOLERABILITY, AND$213,664
M01 · FY2005 · RR
A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A CTL$201,202
M01 · FY2005 · RR
EVALUATION OF HIV INFECTION OR VACCINE INDUCED POSITIVITY IN HIV VACCINE$62,320
M01 · FY2005 · RR
CLINICAL TRIALS FOR THE EVALUATION OF CANDIDATE HIV-1 VACCINES IN NON-HIV-1$35,612
M01 · FY2005 · RR
COMPARATIVE RANDOMIZED STUDY OF SAFETY AND IMMUNOGENICITY OF A NON-ADJUVANTED$28,554
M01 · FY2005 · RR
HVTN 059: PHASE I TRIAL$21,366
M01 · FY2005 · RR
HVTN 057: PHASE I TRIAL$5,342
M01 · FY2005 · RR
A MULTI-SITE EVALUATION OF VIROLOGIC, IMMUNOLOGIC, AND CLINICAL NATURAL HISTO$3,563
M01 · FY2005 · RR
VA CSP#4-3, VARICELLA-ZOSTER VACCINE FOR THE PREVENTION OF HERPES ZOSTER$1,382
M01 · FY2005 · RR
Structure and Dynamics of Protein-Nucleic Acid Complexes$469,250
R01 · FY2004 · GM
Structural basis for CBP/p300 transcriptional regulation$412,070
R01 · FY2004 · CA
Structural Characterization of Globin Folding Pathways$320,861
R01 · FY2004 · DK
Evaluation of HIV Infection or Vaccine Induced Positivity in HIV Vaccine$136,255
M01 · FY2004 · RR
VA CSP#4-3, Varicella-Zoster Vaccine for the Prevention of Herpes Zoster$80,329
M01 · FY2004 · RR
Comparative Randomized Study of Safety and Immunogenicity of a Non-Adjuvanted...$74,277
M01 · FY2004 · RR
A WORLD WIDE, PHASE I, DOSE ESCALATING STUDY OF THE SAFETY, TOLERABILITY, AND..$36,930
M01 · FY2004 · RR
A phase I trial to evaluate the safety, tolerability and immunogenicity of high$29,289
M01 · FY2004 · RR
A phase I trial to evaluate the safety, tolerability and immunogenicity of high$24,193
M01 · FY2004 · RR
CLINICAL TRIALS FOR THE EVALUATION OF CANDIDATE HIV-1 VACCINES IN NON-HIV-1$21,649
M01 · FY2004 · RR
A Multi-Site Evaluation of Virologic, Immunologic, and Clinical Natural Histo...$8,913
M01 · FY2004 · RR
A Probe Study of the Safety, Tolerability, and Immunogenicity of Human Immuno$5,092
M01 · FY2004 · RR
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a Combin$1,272
M01 · FY2004 · RR
Live Attenuated Respiratory Syncytial Virus Vaccine In Heathly$1,101
M01 · FY2004 · RR
Structure and Dynamics of Protein-Nucleic Acid Complexes$469,250
R01 · FY2003 · GM
Structural basis for CBP/p300 transcriptional regulation$412,070
R01 · FY2003 · CA
Structural Characterization of Globin Folding Pathways$320,861
R01 · FY2003 · DK
Acquisition of Console &Cryoprobe for NMR Spectrometer$476,119
S10 · FY2002 · RR
STRUCTURE AND DYNAMICS OF PROTEIN NUCLEIC ACID COMPLEXES$416,726
R01 · FY2002 · GM
Structural Characterization of Globin Folding Pathways$414,555
R01 · FY2002 · DK
Structural basis for CBP/p300 transcriptional regulation$412,070
R01 · FY2002 · CA
DYNAMICS IN MECHANISM OF DIHYDROFOLATE REDUCTASE$145,314
P01 · FY2002 · GM
STRUCTURE AND DYNAMICS OF CATALYTIC ANTIBODIES$0
P01 · FY2002 · CA
STRUCTURE AND DYNAMICS OF PROTEIN NUCLEIC ACID COMPLEXES$384,566
R01 · FY2001 · GM
STRUCTURAL CHARACTERIZATION OF GLOBIN FOLDING PATHWAYS$282,714
R37 · FY2001 · DK
DYNAMICS IN MECHANISM OF DIHYDROFOLATE REDUCTASE$145,314
P01 · FY2001 · GM
STRUCTURE AND DYNAMICS OF CATALYTIC ANTIBODIES$0
P01 · FY2001 · CA
STRUCTURE AND DYNAMICS OF PROTEIN NUCLEIC ACID COMPLEXES$375,009
R01 · FY2000 · GM
STRUCTURAL CHARACTERIZATION OF GLOBIN FOLDING PATHWAYS$276,023
R37 · FY2000 · DK
DYNAMICS IN MECHANISM OF DIHYDROFOLATE REDUCTASE$147,723
P01 · FY2000 · GM
STRUCTURE AND DYNAMICS OF CATALYTIC ANTIBODIES$0
P01 · FY2000 · CA